Lupus & antiphospholipid syndrome
Type I interferon gene expression signature as a marker to predict response to cyclophosphamide based treatment in proliferative lupus nephritis
Authors' conclusion
In proliferative LN, treated with HD or LD-CYC, combined model comprising of decrease in IGS score by 0.81 fold from baseline to three months, along with important histopathological features such as endocapillary hypercellularity and interstitial inflammation had better predictive capability for non-response.
Study context
- Population
- Biopsy-proven proliferative lupus nephritis (LN) patients scheduled to receive high-dose (HD) or low-dose (LD) CYC
- Participants
- 54 patients
- Exposure
- Clinical responders vs non-responders by type I interferon (IFN) gene score
- Outcome
- Prediction of non-response to CYC treatment by IFN-gene based score (IGS) and its change (ΔIGS, baseline to 3 months)
- Follow-up
- 6 months
Methodological detailslongitudinal, 6-month follow-up
- Longitudinal
- 6-month follow-up
Main finding
As reported in the abstract
ΔIGS (baseline to 3 months)
Clinical responders (CR)
−1.339
Non-responders (NR)
−0.563
P = 0.017
- Model (0.81 fold decrease in IGS baseline to 3 months, endocapillary hypercellularity, interstitial inflammation) predicting non-response: sensitivity
- 83.3%
- Same model: specificity
- 71.4%
Observational data: associations, not effects.
Further findings
IGS change baseline to 3 months, by CYC dose
- HD: 2.01 to 1.14
- P = 0.001
- LD: 2.01 to 0.81
- P < 0.001
IGS change 3 to 6 months, by CYC dose
- LD: 0.81 to 1.51
- P = 0.03
- HD: 1.14 to 1.54
- P = 0.300
IGS change baseline to 3 months, by response
- CR: 2.13 to 0.79
- P < 0.001
- NR: 1.83 to 1.27
- P = 0.046
IGS change 3 to 6 months, by response
- CR: 0.79 to 1.57
- P = 0.006
- NR: 1.27 to 1.46
- P = 1
Original publication
Type I interferon gene expression signature as a marker to predict response to cyclophosphamide based treatment in proliferative lupus nephritis. Lupus. Published 20 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →